Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

maybe you are onto something here with respect to scales and using only the worst patients in the study as a subgroup. I need some time to think about it, since the subgroup stuff was not something I have paid any attention to. The problem would be that there are so few patients - i would think, without looking this morning- that meet those criteria- moderate to worse disease at the 200 mg dose.

But I will be only too happy to tip my cap to you if I have it wrong. There must be a slide somewhere that makes your point in the IP slide deck